Endocrine Abstracts

Aims: Lifestyle modification has been shown to prevent development of Type 2 diabetes in high risk American, European and Asian populations. We wanted to test whether such intervention could have similar results in a white Middle Eastern population.Methods: A total of 8212 non-diabetic subjects≥20 years were selected by cluster random sampling method in the cross-sectional phase of the Tehran Lipid and Glucose Study (TLGS) from 1999 to 2001. A subs...

Introduction: The incidence of primary hyperparathyroidism (PHPT) is ~3.5/100 000 per yearThe incidence is on the rise due to increase in ‘routine biochemical testing’Has been thought to be a ‘relatively harmless’ disorder.Some patients tend to undergo surgery, while others are conservatively treated and most followed up for a short period before discharge from follow up.Aims:<l...

Diagnosing malignancy and assessing the prognosis of adrenocortical tumors is challenging. The aim is to identify molecular predictors of malignancy and of survival.Patients and methods: Of 153 unilateral adrenocortical tumors were studied by microarray (n=92) or RT-qPCR (n=148). A 2-gene predictor of malignancy was built using the disease-free survival as the end-point in a training cohort (n=47), then validated in an independent va...

Germline activating mutations of the RET proto-oncogene are associated with inherited medullary thyroid cancer (MTC) and can be also detected in about 10% of apparently sporadic MTC cases. In the present study, 4 novel RET mutations, located in the extracellular domain (A510V, E511K and C531R) and in the intracellular juxtamembrane region (L666N), all identified by the genetic screening on sporadic MTC cases, are firstly reported and functionally characterized. RET Plasmids ca...

Objective: To assess if weekly administration of 40 mg pegvisomant (PEG-V) improves quality of life (QoL) and metabolic parameters in acromegalic patients with already normal age-adjusted insulin-like growth factor-I (IGF-I) concentrations during long-acting somatostatin analog (SSA) treatment.Design: Prospective investigator-initiated, double blind, placebo controlled, cross-over study. Twenty acromegalic subjects received for two consecutive treatment ...